All In Biotech

Drug Trial Radar · NCT07557914

Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes

A Multicenter, Prospective, Single-arm Clinical Study Evaluating the Efficacy and Safety of Epalrestat Combined With Hepatic Arterial Chemotherapy Infusion (HAIC), Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable Hepatocellular Carcinoma and Diabetes

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Jan 21, 2026

Primary completion

Dec 2029

Study completion Dec 2030

Sponsor

Lead sponsor
Haibo ShaoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
First Hospital of China Medical University; Liaoning Cancer Hospital & Institute; The General Hospital of Northern Theater Command; The Affiliated Hospital of Yanbian University; Harbin Medical University Third Affiliated Hospital
First posted
Apr 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the comprehensive therapeutic efficacy and safety profile of the epalrestat combined with hepatic artery infusion chemotherapy (HAIC), donafenib and tislelizumab quadruple regimen in patients with unresectable hepatocellular carcinoma (HCC) and diabetes.

Conditions

  • HCC - Hepatocellular Carcinoma
  • Diabetes

Interventions

  • EpalrestatDrug

    For the first 6 patients in the safety lead-in period, the starting dose of epalrestat was 50 mg, three times per day. If dose-limiting toxicity (DLT) occurred in the first 6 patients, the dose for the second round of 6 patients in the safety lead-in period would be adjusted to 50 mg, twice per day. If DLT occurred in the second round of 6 patients, the dose for the third round of 6 patients in the safety lead-in period would be adjusted to 50 mg, once per day.

  • Donafenib + TislelizumabDrug

    donafenib 0.2g BID, tislelizumab 200mg/21days

  • HAICProcedure

    Include FOLFOX and RALOX.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 12-month Event-free survival (EFS) RateTime frame: From treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs), assessed up to 2 years.

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • Yanbian University Hospital

    Yanji, Jilin, China · Recruiting

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China · Active not recruiting

  • Liaoning Cancer Hospital

    Shenyang, Liaoning, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.